Evidence map›Paper›PMID 36902083›Full record

ReviewInternational journal of molecular sciences2023

Diagnostic Challenges and Solutions in Systemic Amyloidosis.

Rivka Goldis, Batia Kaplan, Olga Lesya Kukuy, Michael Arad, Hila Magen, Efrat Shavit-Stein, Amir Dori, Avi Livneh

Full text readReview
In one paragraph

Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Molecular Research on Amyloidosis.International journal of molecular sciences · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Rivka GoldisDepartment of Neurology, Sheba Medical Center, Tel Hashomer, Ramat Gan 5262000, Israel.
Batia KaplanInstitute of Hematology, Sheba Medical Center, Tel Hashomer, Ramat Gan 5262000, Israel.ORCID 0000-0003-1486-681X
Olga Lesya KukuyInstitute of Nephrology and Hypertension, Sheba Medical Center, Tel Hashomer, Ramat Gan 5262000, Israel.
Michael AradSackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
Hila MagenSackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.ORCID 0000-0002-3990-394X
Efrat Shavit-SteinDepartment of Neurology, Sheba Medical Center, Tel Hashomer, Ramat Gan 5262000, Israel.
Amir DoriDepartment of Neurology, Sheba Medical Center, Tel Hashomer, Ramat Gan 5262000, Israel.ORCID 0000-0003-4633-1481
Avi LivnehDepartment of Medicine, Sheba Medical Center, Tel Hashomer, Ramat Gan 5262000, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amyloidosis refers to a clinically heterogeneous group of disorders characterized by the extracellular deposition of amyloid proteins in various tissues of the body. To date, 42 different amyloid proteins that originate from normal precursor proteins and are associated with distinct clinical forms of amyloidosis have been described. Identification of the amyloid type is essential in clinical practice, since prognosis and treatment regimens both vary according to the particular amyloid disease. However, typing of amyloid protein is often challenging, especially in the two most common forms of amyloidosis, i.e., the immunoglobulin light chain amyloidosis and transthyretin amyloidosis. Diagnostic methodology is based on tissue examinations as well as on noninvasive techniques including serological and imaging studies. Tissue examinations vary depending on the tissue preparation mode, i.e., whether it is fresh-frozen or fixed, and they can be carried out by ample methodologies including immunohistochemistry, immunofluorescence, immunoelectron microscopy, Western blotting, and proteomic analysis. In this review, we summarize current methodological approaches used for the diagnosis of amyloidosis and discusses their utility, advantages, and limitations. Special attention is paid to the simplicity of the procedures and their availability in clinical diagnostic laboratories. Finally, we describe new methods recently developed by our team to overcome limitations existing in the standard assays used in common practice.

Indexed as

Amyloid Neuropathies, FamilialImmunoglobulin Light-chain AmyloidosisAmyloidAmyloidogenic ProteinsHumansProteomicsAmyloidAmyloidogenic Proteinsamyloidosisamyloid typingfree light chain dimersfree light chainsmass spectrometrytransthyretinWestern blotting

Identifiers

PMID36902083
PMCPMC10003318

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read14
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.